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Abstract
Invasive lobular carcinoma (ILC) has been reported to be less responsive to neoadjuvant 
chemotherapy (NAC) than invasive ductal carcinoma (IDC). We sought to determine whether ILC 
histology indeed predicts poor response to NAC by analyzing tumor characteristics such as protein 
expression, gene expression, and imaging features, and by comparing NAC response rates to those 
seen in IDC after adjustment for these factors. We combined datasets from two large prospective 
NAC trials, including in total 676 patients, of which 75 were of lobular histology. Eligible patients 
had tumors ≥ 3 cm in diameter or pathologic documentation of positive nodes, and underwent 
serial biopsies, expression microarray analysis, and MRI imaging. We compared pathologic 
complete response (pCR) rates and breast conservation surgery (BCS) rates between ILC and IDC, 
adjusted for clinicopathologic factors. On univariate analysis, ILCs were significantly less likely to 
have a pCR after NAC than IDCs (11% vs. 25%, p=0.01). However, the known differences in 
tumor characteristics between the two histologic types, including hormone-receptor (HR) status, 
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Her2 status, histological grade, and p53 expression, accounted for this difference with the lowest 
pCR rates among HR+/Her2- tumors in both ILC and IDC (7% and 5%, respectively). ILC which 
were HR- and/or Her2+ had a pCR rate of 25%. Expression subtyping, particularly the NKI 70-
gene signature, was correlated with pCR, although the small numbers of ILC in each group 
precluded significant associations. BCS rate did not differ between IDC and ILC after adjusting 
for molecular characteristics. We conclude that ILC represents a heterogeneous group of tumors 
which are less responsive to NAC than IDC. However, this difference is explained by differences 
in molecular characteristics, particularly HR and Her2, and independent of lobular histology.
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Introduction
Neoadjuvant chemotherapy (NAC) is increasingly used in the treatment of patients with 
large but still operable breast cancer or proven lymph node metastases. Although the overall 
survival benefit is similar to that of adjuvant chemotherapy[1,2], NAC has two main 
advantages. First, reducing the tumor burden in the breast increases the rate of breast-
conservation surgery [3,4]. Second, it allows assessment of tumor response to specific 
chemotherapeutic agents. The conventional outcome measurement of NAC is pathologic 
complete response (pCR) at surgery, which has been shown to be associated with improved 
survival [5,6].
The rates of pCR differ among molecular subtypes, but it is not known how tumor histology 
affects these rates. Invasive breast cancers can be divided into two main histologic subtypes: 
ductal and lobular. Invasive lobular cancers (ILCs) account for 10% of breast cancers, 
comprising a small but important subgroup. They are characterized by loss of the cell 
adhesion marker e-cadherin, and a diffuse growth pattern characterized by non-cohesive 
cells arranged in a single-file pattern [7,8].
ILC and invasive ductal cancer (IDC) differ in expression of standard histopathology 
markers, molecular expression patterns and radiographic appearance [9–11]. Compared to 
IDC, ILCs are more likely to be hormone receptor (HR) positive[12], less likely to be high 
grade, and often appear more diffuse both radiographically and clinically. Some of these 
differences are attributable to differences in cell adhesion resulting from loss of e-cadherin, 
rather than to different anatomical origins, as both ILC and IDC are both derived from the 
terminal duct lobular unit [11].
Several reports have suggested that ILC is less responsive to chemotherapy than IDC and 
thus should be treated with endocrine therapy only [10,13,14]. Similarly, investigators have 
noted a lower pCR rate to NAC among lobular cancers, which may result in a lower rate of 
breast conservation surgery (BCS) than in IDC [15,16]. However it remains unclear whether 
lower rates of pCR and BCS observed in ILC are due to histology or to biologic and 
molecular factors associated with histology, such as HR status [16–19].
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In view of the controversy over the role of NAC in ILC, we compared ILC and IDC in a 
large series of neoadjuvantly treated breast cancer patients for whom MR imaging and gene 
expression data were available. We compared clinical, pathological and molecular features 
of ILC and IDC using pCR and BCS rates as the primary outcome variables. We report the 
combined results from two neoadjuvant studies with a total sample size of 676 locally 
advanced breast cancers, of which 75 were ILCs. We compare molecular characteristics, and 
relate them to differences in pathologic and surgical outcomes for ILC and IDC.
Methods
Subjects
Study subjects were treated through the I-SPY 1 Trial (n = 221) or two ongoing neoadjuvant 
studies at the Netherlands Cancer Institute (NKI, n = 455). The I-SPY 1 Trial was a multi-
center NAC trial in the United States which accrued patients between 2002 and 2006 
[20,21]. Eligible patients were women with invasive breast cancer measuring at least 3 cm 
by clinical examination or imaging, with no evidence of distant metastatic disease. All 
patients received anthracycline-based NAC, with the use of taxanes left to the discretion of 
the treating physicians. After 2005, trastuzumab was given to patients whose tumors were 
HER2+ (n=20). Patients underwent serial core needle biopsies before, during, and after 
NAC, as well as serial MRI examinations.
The two NKI trials accrued 181 and 274 patients between 2004 and 2010. Eligible patients 
had a breast carcinoma with either a primary tumor size of at least 3 cm, or the presence of 
axillary lymph node metastases proven by fine needle aspiration (FNA) [22,23]. A treatment 
regimen was assigned to each patient, consisting of one of the following, depending on the 
study: 1) Six courses of dose-dense doxorubicin/cyclophosphamide (ddAC) or 2) Six 
courses of capecitabine/docetaxel (XD). If the therapy response was considered unfavorable 
by MRI evaluation after three courses, ddAC was changed to XD or vice versa. Patients with 
HER2+ tumors received three 8-week courses of trastuzumab, paclitaxel and carboplatin 
(PTC). Patients underwent serial core needle biopsies before and after NAC. A subset of 
patients (n=138) underwent serial MRI examinations.
Standard pathology biomarkers
All breast pathology slides were reviewed by specialty trained breast pathologists (JW for 
the NKI, CL for the I-SPY 1 trial). A tumor was termed ILC based on histologic growth 
pattern. E-cadherin staining was performed centrally for the I-SPY subjects and NKI 
subjects respectively, but was not included in the definition of ILC. Standard clinical 
biomarkers including hormone receptor and HER2 status were measured at local sites using 
immunohistochemistry and/or fluorescence in-situ hybridization assays (FISH) in the case of 
HER2. P53 expression was assessed by immunohistochemistry, centrally for the I-SPY 1 
patients or at the NKI for the NKI patients. Pathologic complete response (pCR) was defined 
as the absence of invasive tumor in both the breast and axillary lymph nodes after NAC. A 
patient with only residual DCIS or microscopic tumor cells was considered to have a pCR.
Lips et al. Page 3














High quality gene-expression arrays were available on 149 patients from the I-SPY trial 
(Agilent arrays) and 265 patients from the NKI trials (Illumina 6v3 arrays). From the I-Spy 
1 trial, intrinsic subtype classification was determined by PAM50 50-gene assays [24]. The 
70-gene prognostic profile was determined using representative probes as previously 
described and classifies patients as high or low risk for recurrence [25]. The wound healing 
signature was used to classify tumors as quiescent or activated [26].
Imaging data
For I-SPY 1 patients, centrally trained breast radiologists at each site read all MRIs and 
assigned an imaging phenotype for the pre-treatment MRI based on five previously 
described imaging patterns: 1) well defined, unicentric mass; 2) well defined, multilobulated 
mass; 3) area enhancement with nodularity; 4) area enhancement without nodularity; and 5) 
septal spreading[27]. For the subjects enrolled at NKI, a specialized breast radiologist (CL) 
determined whether pre-treatment MRIs showed the tumor to be either mass-like, multi-
nodular, or diffuse. For purposes of analysis, the 5 phenotypes used in the I-SPY 1 Trial 
were collapsed such that phenotypes 1 and 2 were defined as mass-like; phenotype 3 was 
multinodular; and phenotypes 4 and 5 were considered to be diffuse. A consort diagram 
showing availability of pathology biomarker, molecular and imaging data (overall and by 
site) is shown in Figure 1.
Statistical Analysis
Data from the I-SPY 1 and NKI trials were combined and analyzed together, without 
adjustments for site-specific differences. Associations between histologic subtype and other 
clinical, pathological, molecular and imaging parameters were assessed using the chi-square 
test for categorical and Student’s t-test for continuous variables respectively. Pathologic 
complete response and BCS rates for ILCs and IDCs were compared using the Fisher exact 
test over all cases and within subsets defined by histologic subtype-associated variables. 
Associations between pCR and BCS with histologic subtype-associated features were also 
assessed using univariate logistic regression and provided as supplemental results. Data were 
analyzed in Stata Version 11 (College Station, Texas) and JMP 9.0.0 (SAS Institute Inc).
Results
Clinical and Pathological Characteristics of ILC versus IDC
Subjects with ILC were older at diagnosis, more likely to have larger tumors at presentation 
(defined as higher T stage by pre-treatment MRI) and a multinodular pattern on MRI when 
compared to subjects with IDC (Table 1). However, when the analysis was restricted to HR
+/HER2- tumors, there were no significant differences between MRI pattern (60% and 
31.5% multinodular in ILC and IDC, respectively, p=0.099). Race, proportion of patients 
with positive lymph nodes, and chemotherapeutic regimens administered were similar 
between subjects with ILC and IDC.
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Molecular Characteristics of ILC versus IDC
ILC cases were more likely to be HR+/HER2- than IDC cases (79% versus 46%, p<0.001). 
Additionally, ILC cases were less likely to be high grade, and had lower rates of p53 
expression than IDC cases. Overall, 85% of ILC designated on the basis of histopathology 
were negative for e-cadherin.
A subset of cases (41/75 ILC and 368/595 IDC) had evaluable gene expression data. 
Consistent with the HR and HER2 comparison, the Luminal A subtype was more common 
in lobular than ductal cancers (Table 1). Despite the prevalence of the Luminal A subtype, 
ILCs were heterogeneous, with all intrinsic subtypes represented (Table 1). In particular, 
4/41 (10%) of ILCs were found to be of the basal intrinsic subtype, compared to 26% of 
IDC. All 4 basal ILC cases were grade 2; 2 were e-cadherin negative, and 2 were e-cadherin 
positive.
ILC cases had decreased expression of the activated wound healing signature compared to 
IDCs (22% versus 65%, p < 0.001) and lower risk according to 70-gene prognostic profile 
(56% versus 90%, p < 0.001). Significant differences persisted when analysis was restricted 
to HR+ cases only: 18% of HR+ ILC versus 56% of HR+ IDC expressed the activated 
wound healing signature, and 54% of HR+ ILC versus 84% of HR+ IDC had a the high risk 
70-gene prognostic profile in this cohort (data not shown).
Pathologic Response to Neoadjuvant Therapy in ILC versus IDC
ILCs were significantly less likely to have a pCR after NAC than IDCs (11% vs 24%, p = 
0.008). However, ILC and IDC have different clinical, pathological and molecular 
characteristics; and among the 9 variables showing a significant association with histological 
subtype (Table 1), 6 were also significantly correlated with pCR (HR/HER2 subtype, grade, 
p53 expression, molecular subtype, wound healing signature and 70-gene signature risk 
groups, Supplemental Table 1). When we adjusted for these six features, differences in pCR 
rates between ILC and IDC were no longer significant within individual clinical HR/HER2 
subtypes or dichotomized subsets defined by grade (1/2 or 3) and p53 expression (≤75% or 
>75%) (Table 2). Among the 41 ILC cases for which gene expression data were available, 
ILC had significantly lower pCR rates within the 70-gene high risk group than IDCs (4% vs. 
27%, p = 0.013). None of the basal-like ILC had pCR, compared to 41% among the IDC. In 
addition, ILC cases within the wound healing quiescent group also appeared less likely to 
achieve a pCR than their IDC counterparts (0% vs. 15%, p = 0.026).
Surgical Outcomes in ILC versus IDC
Overall, ILCs had a significantly lower rate of successful breast conservation surgery (BCS) 
after NAC than IDCs (33% vs. 46%, Fisher Exact test p = 0.037). However, among the 
clinical, pathological, and molecular features associated with lobular histology, age, T stage 
and MRI pattern were also significantly associated with BCS (Supplemental Table 2). 
Patients over the age of 49 were 1.5 times as likely to have BCS (p = 0.007, 95% CI 1.12–
2.1). Higher T stage at presentation was significantly associated with decreased odds of BCS 
(OR 0.38 for T2 tumors compared to T1, p = 0.006, 95% CI 0.19–0.76), as was a non-mass 
pattern on MRI (OR 0.26 and 0.43, p < 0.001 and p=0.002, 95% CI 0.15–0.44 and 0.26–0.73 
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for multinodular and diffuse patterns respectively when compared to the mass MRI pattern). 
The difference in BCS rates between ILC and IDC were no longer significant when 
evaluated within T stage and MRI pattern defined subsets (Table 3). ILCs remained 
significantly less likely to have BCS than IDCs within the older cohort (32% vs. 54%, p = 
0.021), but not the younger cohort (35% vs. 41%, p = 0.60).
Discussion
While most NAC trials have not distinguished outcome between lobular and ductal cancers, 
those that have done so frequently find lower rates of pCR and BCS in ILC compared to 
IDC. This apparent lack of benefit from NAC has led many to question whether physicians 
should offer NAC to patients with ILC, while others have argued that insufficient evidence 
exists to recommend either for or against its use [9,10,14,18,28]. Many have pointed out that 
lobular histology may be a marker of poor response to NAC because of its association with 
other factors, and not because of a difference intrinsic to lobular histology [16,18,19]. 
However previous studies have had a small number of lobular cancers available for analysis 
precluding the molecular subset analyses that have been performed for ductal cancers.
Given the prevailing belief that: 1) ILC represents a more homogeneous breast cancer type 
than IDC and that 2) ILC demonstrates a homogeneously poor response to NAC, we wished 
to determine whether ILC in fact consisted of different subtypes in which tumor biology 
rather than histology alone could be driving response to NAC. By combining findings from 
three NAC trials which prospectively collected clinical, molecular, and MR imaging data we 
had the opportunity to identify features associated with lobular histology which could 
explain the apparent decreased responsiveness to NAC. We postulated that a sufficiently 
large cohort would allow comparison of biologic and molecular predictors of response to 
NAC between ILC and IDC using the endpoints of pCR and BCS rate.
We confirmed that ILC differed from IDC in clinical presentation, histopathologic 
characteristics, gene expression, and MR imaging features. Subjects with ILC presented at 
older ages with higher T stage, and ILC tumors were more likely to be lower grade, HR+, 
Her2-, and have lower p53 expression. These findings are consistent with previous reports 
[7,10,14,15]. In the combined cohort, pCR was achieved in 11% of ILC and 24% of IDC. 
However, when adjusted for HR and Her2 status, lobular histology was not an independent 
predictor of response to NAC. Regardless of histology, cancers which were HR+/Her2- had 
very low pCR rates (7% and 5% among HR+/Her2- lobular versus ductal cancers, 
respectively). These findings support that tumors with lobular histology generally respond 
poorly to NAC, but that this is due to the enrichment of the HR+/Her2- phenotype among 
ILC, rather than histology.
Only 41 ILC had molecular subtyping. While most of the ILC cases expressed the luminal A 
intrinsic subtype, nearly 10% expressed the basal subtype. These were not due to inclusion 
of pleomorphic lobular cases, as none of the tumors were grade 3. The identification of a 
basal subset within ILC has also been reported by another group which found cytokeratin 
5/6 expression, a commonly accepted marker of the basal subtype, in 17% of ILC cases 
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tested [29]. These observations support that both clinical and molecular heterogeneity exist 
among ILC.
We also found that a proportion of the ILC cases expressed the activated wound healing gene 
expression signature (22% among ILC and 65% among IDC) and more than half had a high 
risk 70 gene prognostic signature (56% in ILC and 90% in IDC), indicating the presence of 
biologically high risk tumors even within the ILC subset. Tumors with an activated wound 
healing signature express genes indicative of a wound healing environment, while tumors 
without expression of these genes are said to be quiescent. The activated wound healing 
signature is associated with poor outcomes [26]. We also compared the 70-gene prognostic 
signature which is a validated profile that identifies patients at a high risk of distant 
metastases and death [25]. The high risk 70-gene prognostic profile has also been found to 
be associated with pCR [30]. In this subset, the low risk signature (found in 43% of ILC and 
10% of IDC) was 100% predictive of failure to achieve pCR among both ILC and IDC, 
again supporting that the ILC phenotype includes a higher prevalence of those molecular 
predictors of poor NAC response when compared to IDC and that these expression patterns 
predict for low pCR rates in both ILC and IDC.
Radiographic findings have emerged as important clinical biomarkers, and baseline MRI 
characteristics in particular have been shown to be an important predictive biomarker of 
neoadjuvant chemotherapy response. In this context, we sought to determine how MR 
findings might differ between invasive ductal and invasive lobular cancers. We found that 
MR imaging features were significantly different between ILC and IDC, but that this 
observation was driven by differences between HR(+) cancers and HR(-) cancers, rather 
than tumor histology. Multinodular and diffuse patterns of enhancement were more prevalent 
among lobular cancers, with mass-like enhancement more commonly seen among ductal 
cancers, specifically among the Her2(+) IDC (35% mass-like) and HR(-) IDC (61% mass-
like) compared to ILC (13% mass-like). Although MR enhancement pattern did not 
independently predict for pCR, a mass-like pattern was associated with a higher breast 
conservation rate among women treated with neoadjuvant therapy among all tumor 
subtypes.
As pCR rates are low in lobular cancer, it is important to consider whether partial response 
rate is also a clinically meaningful goal for neoadjuvant therapy in ILC, since even if a 
patient does not achieve pCR, a partial response can make BCS possible. Methods for more 
quantitative assessment of tumor response have recently been developed, including the 
previously described Residual Cancer Burden and the Neoadjuvant Response Index (NRI) 
[23,32]. Analysis in the NKI cohort using NRI as the outcome yielded the same results as 
the pCR based analysis, indicating that lobular histology is not independently associated 
with lower likelihood of partial response (data not shown). Thus, in the small subset of 
patients with Her2 (+) or HR-negative lobular cancers, or in those patients with a mass-like 
pattern in MRI, there may be a role for NAC in improving outcomes of breast conserving 
surgery, even if pCR is not achieved.
An important limitation of this study is the small number of lobular cases for which 
expression data were available, even with the combined results of three clinical trials. 
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Specifically, we discovered that although the pCR rate was 8/75 (11%) among the total 
group of ILC, only 1 case among the 41 ILC that had expression data (2%) had a pCR. The 
clinical features of those cases with and without microarray data were reviewed, and no 
obvious differences emerged. We confirmed that all microarray assays were performed on 
pretreatment biopsies. Given the small size of samples, the cases subjected to microarray 
analysis were selected for high tumor cellularity; in the lobular cases, those might have 
represented the more chemotherapy resistant tumors. However, the numbers are too small to 
derive definitive answers and the source of this substantial bias remains unclear. Conclusions 
based on these molecular data should therefore be interpreted with caution and confirmation 
in other studies is necessary to understand the clinical role of molecular subtyping in 
predicting response to neoadjuvant therapy in lobular cancers.
In this clinical trial cohort, we confirmed that ILC has a lower pCR rate than IDC in the 
setting of NAC‥ However, this difference could be attributed to clear differences in tumor 
characteristics. Among these patients, HR and Her2 status determined response to NAC 
independent of tumor histology. The lowest pCR rate was seen in HR+/Her2- tumors for 
both ILC and IDC; the low pCR rate in ILC thus reflected the high prevalence of this tumor 
type among lobular cancers. The small subset of HR- and/or Her2+ ILC derived benefit from 
neoadjuvant therapy as demonstrated by a pCR rate of 25% in this group. Molecular 
heterogeneity was found among ILCs including the discovery of biologically high risk 
tumors as defined by high NKI score or activated wound healing signature. Future marker 
studies will allow greater confidence to conclude whether molecular and radiologic 
subtyping can enhance the ability to predict response to chemotherapy above and beyond 
HR and Her2 status.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Clinical, histological and molecular characteristics of the study cohort: Comparison of invasive lobular cancers 
(ILC) and invasive ductal cancers (IDC)
ILC IDC Overall p-value
Mean age (years), t-test (n = 75) (n = 601) (n = 676) 0.004
50 46 47
Race (n = 75) (n = 601) (n = 676) 0.6
  Caucasian 71 (95%) 549 (91%) 620 (92%)
  African American 3 (4%) 39 (6.5%) 42 (6%)
  Other 1 (1%) 13 (2%) 14 (2%)
Tumor stage at presentation (by MRI) (n = 75) (n = 600) (n = 675) 0.001
  T1 0 (0%) 38 (6.3%) 38 (5.6%)
  T2 25 (33%) 289 (48%) 314 (47%)
  T3 44 (59%) 220 (37%) 264 (39%)
  T4 6 (8%) 53 (8.8%) 59 (8.7%)
Node positive (n = 74) (n = 600) (n = 674) 0.11
47 (64%) 435 (73%) 482 (72%)
Chemotherapy regimen (n = 75) (n = 601) (n = 676) 0.32
  AC 29 (39%) 229 (38%) 258 (38%)
  ACT 38 (51%) 259 (43%) 297 (44%)
  ACT and Herceptin 8 (12%) 110 (18%) 118 (18%)
  ACT and Other 0 (0%) 3 (0.5%) 3 (0.4%)
MRI Pattern (n = 46) (n = 385) (n = 431) < 0.001
  Mass 6 (13%) 173 (45%) 179 (42%)
  Multinodular 26 (57%) 101 (26%) 127 (30%)
  Diffuse 14 (30%) 111 (29%) 125 (29%)
Marker subtypes (n =75) (n = 596) (n = 671) <0.001
  HR+/Her2− 59 (79%) 276 (46%) 335 (50%)
  HR+/Her2+ 10 (13%) 82 (14%) 92 (14%)
  HR−/Her2+ 3 (4%) 79 (13%) 82 (12%)
  HR−/Her2− 3 (4%) 159 (27%) 162 (24%)
Grade 3 (n = 51) (n = 436) (n = 487) <0.001
2 (3.9%) 212 (49%) 214 (44%)
p53 expression (IHC) (n = 71) (n = 567) (n = 638) 0.001
  <10% 51 (72%) 267 (47%) 318 (50%)
  10–25% 11 (16%) 84 (15%) 95 (15%)
  26–50% 3 (4.2%) 42 (7.4%) 45 (7.1%)
  51–75% 1 (1.4%) 21 (3.7%) 22 (3.5%)
  >75% 5 (7%) 153 (27%) 158 (25%)
NKI 70-gene risk (n=41) (n=373) (n=414)
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ILC IDC Overall p-value
low risk 18(43%) 37(10%) 55(13%) <0.001
high risk 23(56%) 336(90%) 359(87%)
Molecular subtype (n=41) (n=373) (n=414)
LumA 29(71%) 102(27%) 131(32%) <0.001
LumB 2(5%) 80(21%) 82(20%)
Basal 4(10%) 97(26%) 101(24%)
HER2 2(5%) 64(17%) 66(16%)
Normal 4(10%) 30(8%) 34(8%)
Wound healing signature (n=41) (n=373) (n=414)
quiescent 32(78%) 132(35%) 164(40%) <0.001
activated 9(22%) 241(65%) 250(60%)
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